Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.

Oncotarget - 6 Oct 2015

Artemov Artem, Aliper Alexander, Korzinkin Michael, Lezhnina Ksenia, Jellen Leslie, Zhukov Nikolay, Roumiantsev Sergey, Gaifullin Nurshat, Zhavoronkov Alex, Borisov Nicolas, Buzdin Anton

Abstract excerpt

A new generation of anticancer therapeutics called target drugs has quickly developed in the 21st century. These drugs are tailored to inhibit cancer cell growth, proliferation, and viability by specific interactions with one or a few target proteins. However, despite formally known molecular tar...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Databases, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Enzyme Activation

Share to Molecular Targeted Therapy

Share to Patient Selection

Share to Precision Medicine

Share to Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 26320181
DOI: 10.18632/oncotarget.5119
PMCID: PMC4745731

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26320181-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.PMID 26320181Read ↗

Oncobox Bioinformatical Platform for Selecting Potentially Effective Combinations of Target Cancer Drugs Using High-Throughput Gene Expression DataSemantic proximity Read ↗

Pathway-extended gene expression signatures integrate novel biomarkers that improve predictions of patient responses to kinase inhibitorsSemantic proximity Read ↗

Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer DrugsSemantic proximity Read ↗

An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to DiscoverySemantic proximity Read ↗

Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural ProductsSemantic proximity Read ↗

Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs.Semantic proximity Read ↗

Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products.Semantic proximity Read ↗

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Semantic proximity Read ↗

Kinome-centric pharmacoproteomics identifies signaling pathways underlying cellular responses to targeted cancer drugsSemantic proximity Read ↗

Dr.Paso: Drug response prediction and analysis system for oncology researchSemantic proximity Read ↗

Machine learning prediction of oncology drug targets based on protein and network propertiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.